Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
16.2 ILa | -0.61% | -4.14% | -57.59% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-57.59% | 52.15M | - | ||
+5.66% | 111B | B+ | ||
+11.23% | 105B | B+ | ||
-2.68% | 21.93B | B | ||
-12.15% | 22.34B | B+ | ||
-5.61% | 18.59B | A- | ||
-36.52% | 18.12B | A- | ||
-10.09% | 16.96B | B | ||
+3.33% | 13.7B | C+ | ||
+36.58% | 12.45B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BLRX Stock
- Ratings BioLineRx Ltd.